New Research Shows Psychiatrists Believe More Than Half of Their Patients With Schizophrenia are Non- or Only Partially Adherent

To View a Short Video Presentation on This Research Access the Link https://www.brainshark.com/JanssenADHES/SurveyResults

BEERSE, Belgium, November 29, 2010 - New research showing that psychiatrists believe more than half (53 per
cent) of patients with schizophrenia are non- or partially adherent to
medication was presented today at the International Early Psychosis
Association (IEPA) Congress, Amsterdam (1). The research, conducted by
Janssen, relates to approximately 4.45 million schizophrenia patients in
EMEA (Europe, Middle East and Africa)(2).

Schizophrenia is a devastating mental illness for both the patient and
their family and friends, as it seriously impairs a person's ability to think
clearly, relate to others and to function properly in society. While there is
no cure, many people with the illness respond well to antipsychotic drugs.

Patients who are non-adherent to medication are almost five times more
likely to relapse than those patients who are adherent(3). Frequent relapses
and hospitalisation can increase a person's isolation and make it even more
difficult for them to find and keep a job (4,5,6,7,8). It can also lead to
an increased tendency for violent acts such as suicide and homicide,
particularly when substance abuse is also an issue (9,10).

The ADHES research was taken from a large survey of over 4,500
psychiatrists in 36 countries in the EMEA region(1).

To access the full press release, view a short presentation on
the implications of non-adherence for patients with schizophrenia, including
quotes from esteemed psychiatrists, read a backgrounder on schizophrenia and
its treatment options and for the results of the ADHES survey, please access
the link below:

www.brainshark.com/JanssenADHES/SurveyResults

References:

1. Emsley et al. Poster presented at the IEPA, Amsterdam, Netherlands,
2010.

2. Based on WHO estimated population sizes in the global burden of
disease: 2004 update (p. 32).

3. Kane, J. M. CNS Spectrums. 2007: 12 (10 Suppl 17), 21-26.

4. Thornicroft G, Brohan E, Rose D, et al for the INDIGO Study Group.
Lancet .2009;373(9661):408-15.

5. Marwaha S, Johnson S, Bebbington P, et al. Br J Psychiatry.
2007;191:30-7.

6. Marwaha S, Johnson S. Soc Psychiatry Psychiatr Epidemiol.
2004;39(5):337-49.

7. Nithsdale V, Davies J, Croucher P. J Occup Rehabil. 2008;18(2):175-82.

8. Rosenheck R, Leslie D, Keefe R, et al; CATIE Study Investigators
Group. Am J Psychiatry. 2006;163(3):411-417.

9. Swartz MS, Swanson JW, Hiday VA, et al. Am J Psychiatry.
1998a;155(2):226-31.

10. Swartz MS, Swanson JW, Hiday VA, et al. Soc Psychiatry Psychiatr
Epidemiol. 1998b;33(Suppl 1):S75-80.

Contacts: Sue Silk, Director, Communications & Public Affairs EMEA, Johnson & Johnson Pharmaceutical Services, Tel: +44-1494-553-955, E-mail: ssilk at its.jnj.com; Clare Moggridge, Senior Account Executive, Resoute Communications, Tel: +44-207-357-8187, E-mail: clare.moggridge at resolutecommunications.com